AstraZeneca Acquires Amolyt Pharma with the Aim of Developing Rare Endocrine Disease Treatments

Posted on by admin

Acquisition is highlighted by eneboparatide, Amolyt’s Phase III peptide for hypoparathyroidism with a novel mechanism of action.

Leave a Reply

Your email address will not be published. Required fields are marked *